Novartis AG
Open
$147.50
Prev. Close
$147.50
High
$147.64
Low
$147.50
Market Snapshot
$272.75B
20.2
5.91
$51.72B
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,267 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
emptyResult
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,267 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Recently from Cashu
Novartis Acquires Excellergy to Expand Allergy Treatment Portfolio and Innovate Therapeutic Solutions
Novartis Drives Forward with Strategic Acquisition for Allergy Treatments Swiss pharmaceutical giant Novartis is poised to enhance its portfolio in allergy treatments through the acquisition of U.S.-b…
Novartis Gains FDA Approval for Cosentyx, Expanding Pediatric Treatment Options for Autoimmune Disorders
Novartis Expands Reach with FDA Approval of Cosentyx for Pediatric Use In a significant development for pediatric care in autoimmune disorders, Novartis AG secures U.S. Food and Drug Administration (F…
Novartis AG Gains FDA Approval for Cosentyx in Pediatric Autoimmune Treatment Options
Novartis Expands Pediatric Treatment Options with FDA Approval of Cosentyx Novartis AG announces a major advancement in pediatric healthcare with the recent FDA approval of its anti-inflammatory drug,…
Novartis AG's Cosentyx Receives FDA Approval for Pediatric Autoimmune Conditions Treatment
Novartis AG Secures FDA Approval for Cosentyx in Pediatric Patients In a significant milestone for pediatric healthcare, the U.S. Food and Drug Administration (FDA) recently approves Novartis AG's Cos…